Rituximab for Immune Checkpoint Inhibitor Myasthenia Gravis

The use of immune checkpoint inhibitors (iCPI) in the treatment of multiple cancers has gained prominence due to their high efficacy. However, neurological immune-related adverse events (irAEs) such as myasthenia gravis (MG) have been associated with iCPI therapy. Most of these neurological irAEs ar...

Descripción completa

Detalles Bibliográficos
Autores principales: Verma, Neha, Jaffer, Muhammad, Pina, Yolanda, Peguero, Edwin, Mokhtari, Sepideh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2021
Materias:
Internal Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8357079/
https://www.ncbi.nlm.nih.gov/pubmed/34395120
http://dx.doi.org/10.7759/cureus.16337

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8357079/
https://www.ncbi.nlm.nih.gov/pubmed/34395120
http://dx.doi.org/10.7759/cureus.16337

Ejemplares similares